EMBC
Neutral signalScored 2026-09-10 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Embecta Corp.
- Nom
- Embecta Corp.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $380.2M
- Employés
- 1,850
- PDG
- Devdatt Kurdikar
- Site web
- https://www.embecta.com
- Marché
- AQSTCDNAEBSEVHMRVIMYGN
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 75 000 titres (~364 785,00 $ US) VENTE TOTALE: 6 293 titres (~36 971,38 $ US)
- Insiders
- Morris Milton MayoKurdikar DevdattHOMBACH ROBERT J.
- Total bought
-
$364,785
Avg buy (VWAP, 90d window) $4.85 vs last close —
- Total sold
-
$36,971
Avg sell (VWAP, 90d window) $5.88 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-04
- Last synced
-
2026-09-10 10:26:50
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Morris Milton Mayo | Sell · S | 6,293 | $5.88 | $36,971 | Form 4 |
| 2026-08-12 | Elguicze Jacob | Buy · P | 20,000 | $4.67 | $93,360 | Form 4 |
| 2026-08-12 | HOMBACH ROBERT J. | Buy · P | 45,000 | $4.97 | $223,848 | Form 4 |
| 2026-08-12 | Kurdikar Devdatt | Buy · P | 30,000 | $4.70 | $140,937 | Form 4 |
| 2026-08-12 | Mann Jeffrey Z | Buy · P | 20,000 | $4.99 | $99,800 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-04-01 | Tom Cole | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-10 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
EMBC presents a weak overall profile: a moderate liquidity score (65) is undermined by deeply fragile fundamentals (trend score 45), including negative book value and high leverage that leave little margin for error.
The first sentence of the analysis written for EMBC on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.41 · operating margin 30%
Market snapshot
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 62.9% | 64.9% | 66.9% | 68.6% | 68.7% | |
| Ebit Margin | 22.5% | 13.9% | 19.0% | 26.8% | 42.5% | |
| Ebitda Margin | 27.3% | 17.7% | 21.9% | 29.6% | 45.8% | |
| Operating Profit Margin | 30.5% | 15.5% | 20.5% | 33.5% | 42.2% | |
| Pretax Profit Margin | 12.6% | 3.9% | 9.4% | 22.7% | 42.5% | |
| Continuous Operations Profit Margin | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | |
| Net Profit Margin | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | |
| Bottom Line Profit Margin | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | |
| Current Ratio | 2.415 | 2.035 | 2.119 | 2.208 | 1.780 | |
| Quick Ratio | 1.732 | 1.576 | 1.689 | 1.800 | 1.061 | |
| Solvency Ratio | 0.084 | 0.060 | 0.051 | 0.129 | 2.334 | |
| Cash Ratio | 0.862 | 0.715 | 0.923 | 1.099 | 0.000 | |
| Price To Earnings Ratio | 8.604 | 10.522 | 12.236 | 7.344 | 6.430 | |
| Price To Earnings Growth Ratio | 0.384 | 1.177 | -0.178 | -0.158 | -2.538 | |
| Forward Price To Earnings Growth Ratio | 0.384 | 1.177 | -0.178 | -0.158 | -2.538 | |
| Price To Earnings Diluted Ratio | 8.710 | 10.522 | 12.336 | 7.401 | 6.430 | |
| Price To Earnings Diluted Growth Ratio | 0.417 | 1.070 | -0.180 | -0.158 | -2.538 | |
| Price To Book Ratio | -1.263 | -1.114 | -1.048 | -1.843 | 4.495 | |
| Price To Sales Ratio | 0.762 | 0.732 | 0.769 | 1.454 | 2.292 | |
| Price To Free Cash Flow Ratio | 4.511 | 41.326 | 20.908 | 4.231 | 6.402 | |
| Price To Operating Cash Flow Ratio | 4.292 | 23.036 | 12.724 | 3.985 | 5.855 | |
| Debt To Assets Ratio | 1.311 | 1.251 | 1.349 | 1.513 | 0.005 | |
| Debt To Equity Ratio | -2.196 | -2.179 | -1.994 | -1.844 | 0.007 | |
| Debt To Capital Ratio | 1.836 | 1.849 | 2.006 | 2.185 | 0.007 | |
| Long Term Debt To Capital Ratio | 1.883 | 1.893 | 2.064 | 2.261 | 0.000 | |
| Financial Leverage Ratio | -1.675 | -1.741 | -1.478 | -1.219 | 1.327 | |
| Working Capital Turnover Ratio | 2.855 | 2.870 | 2.952 | 4.594 | 10.310 | |
| Operating Cash Flow Ratio | 0.733 | 0.095 | 0.192 | 1.369 | 2.780 | |
| Operating Cash Flow Sales Ratio | 0.177 | 0.032 | 0.060 | 0.365 | 0.391 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.951 | 0.557 | 0.609 | 0.942 | 0.914 | |
| Debt Service Coverage Ratio | 2.173 | 1.914 | 1.803 | 5.413 | 0.000 | |
| Interest Coverage Ratio | 3.069 | 1.551 | 2.146 | 8.184 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 20.179 | 3.758 | 7.126 | 43.389 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.134 | 0.022 | 0.041 | 0.251 | 111.220 | |
| Capital Expenditure Coverage Ratio | 20.613 | 2.259 | 2.555 | 17.175 | 11.692 | |
| Dividend Paid And Capex Coverage Ratio | 4.327 | 0.710 | 1.112 | 12.644 | 11.692 | |
| Dividend Payout Ratio | 0.367 | 0.441 | 0.489 | 0.038 | 0.000 | |
| Enterprise Value Multiple | 6.880 | 10.871 | 8.857 | 8.836 | 5.017 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 62.9% | ▼-2.0% | ▼-3.5% |
| Ebit Margin | 22.6% | ▲8.6% | ▼-2.4% |
| Ebitda Margin | 27.3% | ▲9.6% | ▼-1.2% |
| Operating Profit Margin | 30.5% | ▲15.0% | ▲2.0% |
| Pretax Profit Margin | 12.6% | ▲8.7% | ▼-5.6% |
| Continuous Operations Profit Margin | 8.8% | ▲1.9% | ▼-6.7% |
| Net Profit Margin | 8.8% | ▲1.9% | ▼-6.7% |
| Bottom Line Profit Margin | 8.8% | ▲1.9% | ▼-6.7% |
| Current Ratio | 2.414 | ▲0.380 | ▲0.303 |
| Quick Ratio | 1.732 | ▲0.155 | ▲0.160 |
| Solvency Ratio | 0.084 | ▲0.024 | ▼-0.447 |
| Cash Ratio | 0.862 | ▲0.147 | ▲0.142 |
| Price To Earnings Ratio | 8.604 | ▼-1.919 | ▼-0.423 |
| Price To Earnings Growth Ratio | 0.384 | ▼-0.792 | ▲0.647 |
| Forward Price To Earnings Growth Ratio | 0.384 | ▼-0.792 | ▲0.647 |
| Price To Earnings Diluted Ratio | 8.710 | ▼-1.812 | ▼-0.370 |
| Price To Earnings Diluted Growth Ratio | 0.417 | ▼-0.653 | ▲0.695 |
| Price To Book Ratio | -1.263 | ▼-0.149 | ▼-1.109 |
| Price To Sales Ratio | 0.761 | ▲0.029 | ▼-0.440 |
| Price To Free Cash Flow Ratio | 4.511 | ▼-36.816 | ▼-10.965 |
| Price To Operating Cash Flow Ratio | 4.292 | ▼-18.744 | ▼-5.686 |
| Debt To Assets Ratio | 1.311 | ▲0.060 | ▲0.225 |
| Debt To Equity Ratio | -2.196 | ▼-0.018 | ▼-0.555 |
| Debt To Capital Ratio | 1.836 | ▼-0.013 | ▲0.259 |
| Long Term Debt To Capital Ratio | 1.883 | ▼-0.010 | ▲0.263 |
| Financial Leverage Ratio | -1.675 | ▲0.066 | ▼-0.718 |
| Working Capital Turnover Ratio | 2.855 | ▼-0.015 | ▼-1.861 |
| Operating Cash Flow Ratio | 0.733 | ▲0.638 | ▼-0.301 |
| Operating Cash Flow Sales Ratio | 0.177 | ▲0.146 | ▼-0.028 |
| Free Cash Flow Operating Cash Flow Ratio | 0.952 | ▲0.394 | ▲0.157 |
| Debt Service Coverage Ratio | 2.173 | ▲0.259 | ▼-0.088 |
| Interest Coverage Ratio | 3.069 | ▲1.518 | ▲0.079 |
| Short Term Operating Cash Flow Coverage Ratio | 20.179 | ▲16.421 | ▲5.288 |
| Operating Cash Flow Coverage Ratio | 0.134 | ▲0.112 | ▼-22.200 |
| Capital Expenditure Coverage Ratio | 20.613 | ▲18.353 | ▲9.754 |
| Dividend Paid And Capex Coverage Ratio | 4.327 | ▲3.618 | ▼-1.770 |
| Dividend Payout Ratio | 0.367 | ▼-0.074 | ▲0.100 |
| Enterprise Value Multiple | 6.880 | ▼-3.991 | ▼-1.212 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $822.7M | $822.4M | $861.4M | $1.64B | $2.67B | |
| Enterprise value | $2.03B | $2.16B | $2.17B | $2.96B | $2.67B | |
| EV / Sales | 1.88x | 1.93x | 1.94x | 2.62x | 2.29x | |
| EV / Op. cash flow | 10.58x | 60.60x | 32.11x | 7.17x | 5.86x | |
| EV / Free cash flow | 11.12x | 108.71x | 52.76x | 7.61x | 6.41x | |
| EV / EBITDA | 6.88x | 10.87x | 8.86x | 8.84x | 5.02x | |
| Net debt / EBITDA | 4.09x | 6.74x | 5.35x | 3.92x | 0.01x | |
| Current ratio | 2.42x | 2.04x | 2.12x | 2.21x | 1.78x | |
| Income quality | 2.01x | 0.46x | 0.96x | 1.84x | 1.10x | |
| Graham number | — | — | — | — | $41 | |
| Graham net-net | -$23 | -$25 | -$28 | -$27 | -$0 | |
| Tax burden | 70.0% | 177.1% | 66.6% | 87.1% | 83.8% | |
| Interest burden | 56.0% | 28.2% | 49.7% | 84.7% | 100.0% | |
| Working capital | $369.9M | $387.0M | $395.6M | $363.7M | $128.0M | |
| Invested capital | $649.5M | $701.1M | $743.5M | $689.9M | $613.0M | |
| Return on assets | 8.7% | 6.1% | 5.8% | 20.6% | 52.6% | |
| Operating ROA | 27.7% | 13.9% | 20.0% | 40.3% | 64.5% | |
| Return on tangible assets | 8.9% | 6.2% | 5.9% | 21.1% | 55.0% | |
| Return on equity | -14.6% | -10.6% | -8.6% | -25.1% | 69.8% | |
| Return on invested capital | 27.4% | 18.8% | 17.4% | 41.3% | 66.0% | |
| Return on capital employed | 39.7% | 19.1% | 26.7% | 48.1% | 78.8% | |
| Earnings yield | 11.6% | 9.5% | 8.2% | 13.6% | 15.5% | |
| Free cash flow yield | 22.2% | 2.4% | 4.8% | 23.6% | 15.6% | |
| Capex / Op. cash flow | 4.9% | 44.3% | 39.1% | 5.8% | 8.6% | |
| Capex / Depreciation | 22.9% | 43.6% | 81.3% | 75.7% | 102.6% | |
| Capex / Sales | 0.9% | 1.4% | 2.4% | 2.1% | 3.3% | |
| SG&A / Sales | 30.7% | 32.5% | 30.5% | 26.1% | 20.6% | |
| R&D / Sales | 2.0% | 7.0% | 7.6% | 5.8% | 5.4% | |
| Stock comp / Sales | 2.9% | 2.3% | 1.9% | 1.7% | 1.1% | |
| Intangibles / Total assets | 2.1% | 1.8% | 2.0% | 2.3% | 4.3% | |
| Days sales outstanding | 50d | 81d | 6d | 8d | 47d | |
| Days payables outstanding | 68d | 84d | 53d | 43d | 54d | |
| Operating cycle | 213d | 239d | 156d | 134d | 165d | |
| Cash conversion cycle | 145d | 155d | 103d | 91d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap +0.0%EV / Sales ▼-2.6%EV / EBITDA ▼-36.7%EV / Op. cash flow ▼-50.020Earnings yield ▲+0.021
Profitability
Return on equity ▼-0.040Return on assets ▲+0.027Return on invested capital ▲+0.085Return on capital employed ▲+0.206Operating ROA ▲+0.138Income quality ▲+1.553Tax burden ▼-1.072
Efficiency
Days sales outstanding ▼-30.294Days payables outstanding ▼-16.704Operating cycle ▼-26.484Cash conversion cycle ▼-9.780Capex / Sales ▼-0.005R&D / Sales ▼-0.050
Balance-sheet strength
Current ratio ▲+0.380Net debt / EBITDA ▼-2.650Working capital ▼-17100000.000Invested capital ▼-51600000.000Intangibles / Total assets ▲+0.002
Change over 5 years
Valuation
Market cap ▼-69.2%EV / Sales ▼-18.2%EV / EBITDA ▲+37.1%EV / Op. cash flow ▲+4.713Earnings yield ▼-0.039
Profitability
Return on equity ▼-0.845Return on assets ▼-0.439Return on invested capital ▼-0.386Return on capital employed ▼-0.391Operating ROA ▼-0.368Income quality ▲+0.911Tax burden ▼-0.138
Efficiency
Days sales outstanding ▲+3.120Days payables outstanding ▲+13.356Operating cycle ▲+47.727Cash conversion cycle ▲+34.371Capex / Sales ▼-0.025R&D / Sales ▼-0.034
Balance-sheet strength
Current ratio ▲+0.634Net debt / EBITDA ▲+4.081Working capital ▲+241900000.000Invested capital ▲+36500000.000Intangibles / Total assets ▼-0.023
Employee count
Peer market caps
Recent news
- 2026-09-02 EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC).
- 2026-08-31 embecta to Participate in Investor Events In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
- 2026-08-26 EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company''s leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
- 2026-08-24 The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC''s high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize.
- 2026-08-18 EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company''s leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
- 2026-08-18 EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company''s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
- 2026-08-17 CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026 NEW YORK--(BUSINESS WIRE)---- $EMBC #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.
- 2026-08-17 EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit PR Newswire NEW YORK
- 2026-08-17 EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. So what: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-17 Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).